&w=3840&q=100)
Substandard quality in 3,104 drugs, 245 found spurious in FY25: JP Nadda
Rahul Goreja New Delhi
Between April 2024 and March 2025, a total of 3,104 drug samples were declared not of standard quality, while 245 were found to be spurious or adulterated, the government informed the Rajya Sabha on Tuesday. These results came from 1,16,323 drug samples tested across the country during the period.
The data was shared by Union Health Minister Jagat Prakash Nadda in response to a question on the prevalence of substandard and spurious drugs in the country.
Nadda also stated that between April 2023 and March 2024, a total of 1,06,150 drug samples were tested, out of which 2,988 were found to be not of standard quality and 282 were identified as spurious.
Risk-based inspections and regulatory action
Since December 2022, the Central Drugs Standard Control Organisation (CDSCO) has inspected 905 drug manufacturing and testing units, resulting in 694 regulatory actions, including stop production or testing orders, licence suspensions or cancellations, warning letters, and show-cause notices, Nadda said.
He further added that manufacturers whose drugs fail quality checks are required to immediately recall and halt further distribution of those batches.
As for whether the government plans to publish a list of compliant drug manufacturers to rebuild public trust, Nadda said that CDSCO already uploads alerts about drugs declared not of standard quality, spurious, misbranded or adulterated on its website under the 'Drug Alert' section.
Funding and policy initiatives
To address broader challenges in drug quality, the government is implementing the Strengthening of Pharmaceutical Industry (SPI) scheme, which includes support for common facilities, technology upgrades for small and medium enterprises, and promotion of research and knowledge-sharing.
The ministry of health and family welfare is also running a centrally sponsored scheme - Strengthening of States' Drug Regulatory System (SSDRS) - with an approved outlay of ₹850 crore, Nadda said, adding that the funding has supported the construction of 17 new drug testing labs and the upgradation of 24 existing labs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 hours ago
- Time of India
Late Bhanutai Gadkari Memorial Diagnostic Centre inaugurated: MRI at Rs1,200, CT Scan at Rs800, X-ray at Rs100
Nagpur: A state-of-the-art 6,000 sq ft facility in north Nagpur will be offering essential diagnostic and dialysis services at some of the lowest rates in the country — MRI for Rs1,200, CT Scan for Rs800, and digital X-ray for just Rs100, and major blood tests at Rs300, which otherwise cost thousands. Remarkably, it is India's first diagnostic centre equipped entirely with "Made-in-India" machines. The late Bhanutai Gadkari Memorial Diagnostic Centre, which was inaugurated on Sunday, has come as a major boost for healthcare infrastructure in north Nagpur. Located at Kamal Chowk, Lashkaribagh, the centre is dedicated to memory of Bhanutai Gadkari, mother of Union minister for road transport and highways, Nitin Gadkari, who presided over the programme when chief minister Devendra Fadnavis inaugurated the facility. "This diagnostic centre will be a milestone in the healthcare sector. Combining empathy with service, it sets an example of how indigenous technology can be used to bring down the cost of essential diagnostics for the common man," said Fadnavis while praising Gadkari's initiative. Gadkari, on an emotional note, said that the centre is not a commercial project, but a service mission inspired by his mother's legacy for compassion and empathy. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Your IQ Is 140 If You Can Answer 10 of These Questions Correctly. IQ International Undo by Taboola by Taboola "From my first day in public life, her blessings guided me to serve the poor and suffering," said Gadkari and made an appeal to include bone marrow, sickle cell and thalassaemia treatments under the Mahatma Jyotiba Phule Jan Arogya Yojana. The fully air-conditioned centre, run by the late Bhanutai Gadkari Gramin Vikas Sanstha, features a modern waiting area, paperless operations, high-capacity servers, and trained technical staff. All MRI and CT scan machines have been manufactured in India, in collaboration with AMTZ (Andhra Pradesh MedTech Zone), significantly cutting costs compared to imported equipment. "This is the first time in India that a diagnostic centre has been established with 100% indigenous machines. We used to import MRI machines for Rs6 crore. Now, we are making them at Rs2 crore and exporting them too," said Dr Jitendra Sharma, managing director of AMTZ. # WHAT CENTRE OFFERS MRI – Rs1,200: High-end 1.5 Tesla imaging with 16-channel MUSIC technology ensuring quick scans with excellent image quality CT Scan — Rs800: BIS, AERB and CDSCO-approved fast scanning machines. Full chest scans done in just 6 seconds Digital X-ray — Rs100; high-resolution, modern digital imaging Dialysis — Rs750 standard, only Rs250 if NMC provides ₹500 subsidy—free dialysis for donor-backed patients Pathology Tests — Rs300; over 40 common tests included Pharmacy — Generic medicines available at 10% discount
Time of India
13 hours ago
- Time of India
Lack of hepatitis awareness makes detection hard: Docs
Ranchi: Despite availability of screening facilities, hepatitis diagnosis remains poor in rural parts of Jharkhand owing to the lack of awareness among rural population hindering countrywide hepatitis C elimination mission by 2030, health experts said on the eve of World Hepatitis Day, on Sunday. According to the data provided by the minister of state in the ministry of health and family welfare, Anupriya Patel at the Rajya Sabha in March this year, Jharkhand has reported 41 deaths due to hepatitis-B in the last five financial years. While, the highest deaths, 15 were reported in FY 2020-21, two deaths recorded in FY 2019-20 and FY 2023-24, seven in FY 2021-22, 11 in FY 2022-23 and four deaths have been reported in FY 2024-25 (till Dec 2024). Health experts believe the actual number could be higher, as many cases go unreported or undetected, particularly in remote areas. Dr Uma Sinha, former nodal officer of National Viral Hepatitis Control Program (NHVCP) in Jharkhand, who retired last month, said despite the availability of treatment centres across all the districts in the state, people in rural areas are often unaware of the symptoms and severity of the disease and they go undetected. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo "NHVCP's aim is to combat hepatitis and achieve countrywide elimination of hepatitis C by 2030, but in Jharkhand due to low screening rate particularly in the rural areas there is an absence of clear picture about this communicable disease. But it is sure that the cases are not decreasing in Jharkhand as screening rate is very poor in rural pockets. Another possible reason could be that the zero dose usually provided to the newborn within 24 hours of birth, are not being given due to the absence of vaccines in rural health centres," Sinha added. Jharkhand has a total of 27 treatment centres in the state, Sinha said. In Ranchi's Rims, around 3,000 patients of hepatitis B and around 500 hepatitis C are currently undergoing treatment. Dr Rashmi Sinha, associate professor at the medicine department in RIMS said that the hospital has witnessed an increased number of hepatitis B patients in recent times. "Screening rate is satisfactory in urban health centres like Rims which has led to an improved detection rate," Sinha added.
NDTV
18 hours ago
- NDTV
Centre Flags Carcinogen Fears On Acidity Medicine Ranitidine, Orders Probe
New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure manufacturers of Ranitidine -- a commonly used acidity medicine --monitor NDMA levels, a potentially cancer-causing impurity, in both the active pharmaceutical ingredient (API) and formulations of the drug. The CDSCO has also suggested reducing the shelf life as a precautionary step. The move comes from the Drugs Controller General of India (DCGI), Dr Rajeev Singh Raghuvanshi, following a recommendation by the Drugs Technical Advisory Board (DTAB) during its 92nd meeting on April 28, 2025. The Board reviewed a report submitted by an expert committee constituted in December last year to study the impurity concerns around Ranitidine. Based on this, DTAB has called for a larger committee to examine all aspects of the issue, including storage conditions that may contribute to NDMA formation. In addition, the Board recommended that the Indian Council of Medical Research (ICMR) conduct a study to further assess the long-term safety of Ranitidine in light of NDMA presence. Manufacturers have now been told to adopt risk-based measures, such as limiting shelf life, modifying storage recommendations, and enhancing NDMA testing protocols across their supply chains. "Ranitidine falls in the Group 2A carcinogen category, according to the International Agency for Research on Cancer (IARC), which implies that it is a probable human carcinogen. It should not be continued in prescription when there are safer alternatives such as Famotidine and Pantoprazole available," said Dr Abhishek Shankar, Oncologist, AIIMS Delhi. NDMA is classified as a probable human carcinogen, and its presence in medications has triggered global regulatory scrutiny over recent years. Ranitidine, commonly prescribed for acid reflux and ulcers, was withdrawn from several markets, including the US, after alarmingly high levels of NDMA were found in some samples. "Ranitidine was commonly prescribed in the past. Its usage has reduced in most metro cities, but it is still prescribed in Tier 1 or 2 cities, particularly at primary healthcare centres. In my knowledge, the drug has been known to have NDMA impurities; the FDA has also ruled out the use of this drug in large doses. The DGCI needs to set prescribed limits for NDMA levels in this drug," said Dr Lohit Chauhan, Gastroenterologist at Max Dwarka.
